Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | Decitabine, venetoclax, and IDH inhibitor in IDH-mutated AML

Himachandana Atluri, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents promising safety and efficacy data from a trial evaluating the combination of decitabine, venetoclax, and an IDH inhibitor in the treatment of patients with IDH-mutated acute myeloid leukemia (AML). The findings reveal favorable composite remission rates (CRc) for both newly diagnosed and relapsed/refractory (R/R) patients, with manageable adverse events (AEs). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.